ScreenerHero

IPHA Innate Pharma S.A.

NAS · US · Healthcare · Biotechnology · innate-pharma.com
1.520USD-4.40%Mkt Cap: 169.78M $P/E: —

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap169.78M USD
Enterprise Value158.29M USD
Revenue (TTM)9.81M USD
Gross Profit-30.17M USD
Net Income (TTM)-49.18M USD
Revenue/Share0.10 USD
Last Price1.520 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees120
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.37
PEG—
EV/EBITDA-3.37
EV/Revenue16.14
P/S18.11
P/B-3.25
EPS (TTM)-0.59
EPS (Forward)-0.47
52W Range
1.17023% of range2.710
52W High2.710 USD
52W Low1.170 USD
Profitability
Gross Margin0.00%
Oper. Margin-335.70%
EBITDA Margin0.00%
Profit Margin-1764.51%
ROE226.58%
ROA-78.41%
Growth
Revenue Growth16.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.56M USD
CapEx (TTM)2.35M USD
FCF Margin-295.30%
FCF Yield-17.06%
Net Debt9.31M USD
Net Debt/EBITDA-0.20
Balance Sheet
Debt/Equity-1.04
Current Ratio0.60
Quick Ratio0.47
Book Value/Sh-0.49 USD
Cash/Share0.12 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)6.667 USD
Upside (mean)+338.6%
Target Range4.000 USD – 9.000 USD
4.000+338.6% to mean9.000
# Analysts3
Ownership
Shares Out.111.70M
Float70.45M
Insiders1.40%
Institutions0.35%
Short Interest
Short Ratio2.2d
Short % Float0.07%
Short % Out.0.07%
Shares Short76.07K
Short (prev mo.)227.04K
Technical
SMA 501.948 (-22.0%)
SMA 2001.738 (-12.6%)
Beta1.19
S&P 52W Chg16.45%
Avg Vol (30d)45.84K
Avg Vol (10d)50.33K
Technical Indicators
RSI (14)29.9
MACD-0.1180
MACD Signal-0.0978
MACD Hist.-0.0202
BB Upper2.050 USD
BB Middle1.748 USD
BB Lower1.445 USD
BB Width34.59%
ATR (14)0.1240 USD
Vol Ratio (20d)0.25x